Horizon Technology Finance Management
Horizon Technology Finance Management, LLC is a venture lending firm that specializes in providing structured debt products, including senior and subordinated venture loans, secured working capital loans, and equipment loans, to development-stage companies primarily in the technology and life sciences sectors. Founded in 2003 and headquartered in Farmington, Connecticut, with additional offices in Pleasanton, California, and Reston, Virginia, Horizon focuses on investments in areas such as cloud computing, biotechnology, and alternative energy. The firm targets companies in the Mid-Atlantic and Western regions of the United States, offering loans ranging from $1 million to $25 million, with repayment terms of up to 48 months. With a team that has collectively originated over $5 billion in venture loans, Horizon aims to support innovative companies by providing essential capital to fuel their growth.
Onkos Surgical
Debt Financing in 2025
Onkos Surgical Inc. is a privately-held company based in Parsippany, New Jersey, focused on providing advanced technologies and solutions for surgical oncologists. Founded in 2014, Onkos Surgical is dedicated to transforming the treatment of musculoskeletal cancers and complex orthopedic conditions. The company offers innovative products such as GenVie, a magnesium bone scaffolding technology, and the ELEOS Proximal Tibia, a 3D printed limb salvage replacement. By leveraging cutting-edge techniques in virtual surgical planning, 3D modeling and printing, and personalized surgical planning, Onkos Surgical aims to enhance patient outcomes and improve the overall experience for both patients and healthcare professionals.
PDS Biotechnology
Post in 2022
PDS Biotechnology Corporation is a clinical-stage biopharmaceutical company based in North Brunswick, New Jersey, focused on developing immunotherapies for cancer and infectious diseases. Founded in 2005, the company aims to prevent and treat various cancers, including cervical, ovarian, melanoma, leukemia, pancreatic, oral, multiple myeloma, anal, and vulvar cancers. PDS Biotechnology's product pipeline includes PDS0101, a treatment for HPV-related cancers; PDS0102, a pandemic influenza vaccine; and PDS0103, a series of immunotherapy products for non-viral cancers. The company's proprietary Versamune platform technology is designed to activate and direct the human immune system to effectively target and attack cancer cells, supporting its commitment to innovative cancer treatment solutions.
Palatin Technologies
Post in 2014
Palatin Technologies is a biopharmaceutical company focused on developing targeted, receptor-specific peptide therapeutics to address significant unmet medical needs. Based in Cranbury, New Jersey, the company’s lead product is Vyleesi, a melanocortin receptor agonist designed for the treatment of premenopausal women with hypoactive sexual desire disorder. Palatin is also advancing several other candidates, including oral PL8177, which targets inflammatory bowel diseases, and systemic PL8177, aimed at treating non-infectious uveitis and COVID-19. Additionally, the company is developing PL9643 for anti-inflammatory ocular conditions like dry eye disease, as well as PL3994 and PL5028, which target cardiovascular and fibrotic diseases. Their research emphasizes the modulation of melanocortin and natriuretic peptide receptor systems to resolve inflammation and facilitate tissue healing, with applications extending to various conditions, including obesity, erectile dysfunction, and pulmonary diseases.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.